Difference between revisions of "Myelodysplastic syndrome"
Warner-admin (talk | contribs) m (Text replacement - "http://www.annals.org/content/137/3/156.long" to "https://doi.org/10.7326/0003-4819-137-3-200208060-00007") |
Warner-admin (talk | contribs) m (Text replacement - "http://www.lrjournal.com/article/S0145-2126(14)00296-3" to "https://doi.org/10.1016/j.leukres.2014.09.014") |
||
Line 1,218: | Line 1,218: | ||
|style="background-color:#91cf61"|Phase 2 | |style="background-color:#91cf61"|Phase 2 | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1016/j.leukres.2014.09.014 Thepot et al. 2014 (GFM-ERLOTINIB-08)] |
|NR in abstract | |NR in abstract | ||
|style="background-color:#91cf61"|Phase 1/2 | |style="background-color:#91cf61"|Phase 1/2 | ||
Line 1,231: | Line 1,231: | ||
<!-- Data presented at American Society of Hematology (ASH) 2011 Meeting, abstract # 1714. --> | <!-- Data presented at American Society of Hematology (ASH) 2011 Meeting, abstract # 1714. --> | ||
# '''MCC-15961:''' Komrokji RS, Padron E, Yu D, Fulp WJ, Rodriguez Y, Tinsley S, List AF, Lancet JE. Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes. Am J Hematol. 2014 Aug;89(8):809-12. Epub 2014 May 16. [https://doi.org/10.1002/ajh.23749 link to full article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4561860/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/24764152 PubMed] NCT00977548 | # '''MCC-15961:''' Komrokji RS, Padron E, Yu D, Fulp WJ, Rodriguez Y, Tinsley S, List AF, Lancet JE. Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes. Am J Hematol. 2014 Aug;89(8):809-12. Epub 2014 May 16. [https://doi.org/10.1002/ajh.23749 link to full article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4561860/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/24764152 PubMed] NCT00977548 | ||
− | # '''GFM-ERLOTINIB-08:''' Thepot S, Boehrer S, Seegers V, Prebet T, Beyne-Rauzy O, Wattel E, Delaunay J, Raffoux E, Hunault M, Jourdan E, Chermat F, Sebert M, Kroemer G, Fenaux P, Adès L; Groupe Francophone des Myelodysplasies. A phase I/II trial of erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure. Leuk Res. 2014 Dec;38(12):1430-4. Epub 2014 Oct 7. [ | + | # '''GFM-ERLOTINIB-08:''' Thepot S, Boehrer S, Seegers V, Prebet T, Beyne-Rauzy O, Wattel E, Delaunay J, Raffoux E, Hunault M, Jourdan E, Chermat F, Sebert M, Kroemer G, Fenaux P, Adès L; Groupe Francophone des Myelodysplasies. A phase I/II trial of erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure. Leuk Res. 2014 Dec;38(12):1430-4. Epub 2014 Oct 7. [https://doi.org/10.1016/j.leukres.2014.09.014 link to original article] [https://pubmed.ncbi.nlm.nih.gov/25449687 PubMed] |
==Midostaurin monotherapy {{#subobject:badb27|Regimen=1}}== | ==Midostaurin monotherapy {{#subobject:badb27|Regimen=1}}== | ||
<div class="toccolours" style="background-color:#eeeeee"> | <div class="toccolours" style="background-color:#eeeeee"> |
Revision as of 23:44, 21 November 2022
Section editor | |
---|---|
Sanjay R. Mohan, MD, MSCI Vanderbilt University Nashville, TN |
24 regimens on this page
43 variants on this page
|
Note: this page has historically been focused on disease-modifying regimens, as opposed to regimens intended to decrease transfusion requirements such as erythropoietin. As such, most regimens are for higher-risk MDS. For patients with bone marrow blast percentage greater than 10%, there is a large overlap with acute myeloid leukemia regimens; please see the AML page for regimens.
Guidelines
ELN
- 2013: Malcovati et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet
ESMO
- 2014: Fenaux et al. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
"How I treat"
- 2019: Santini How I treat MDS after hypomethylating agent failure
- 2013: Sekeres & Cutler How we treat higher-risk myelodysplastic syndromes PubMed
- 2013: Fenaux & Adès How we treat lower-risk myelodysplastic syndromes
International expert panel
- 2017: de Witte et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel PubMed
NCCN
Lower-risk MDS, all lines of therapy
Azacitidine oral monotherapy
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Garcia-Manero et al. 2021 (AZA-MDS-003) | 2013-2018 | Phase 3 (E-esc) | Placebo | Superior transfusion independence |
References
- AZA-MDS-003: Garcia-Manero G, Santini V, Almeida A, Platzbecker U, Jonasova A, Silverman LR, Falantes J, Reda G, Buccisano F, Fenaux P, Buckstein R, Diez Campelo M, Larsen S, Valcarcel D, Vyas P, Giai V, Olíva EN, Shortt J, Niederwieser D, Mittelman M, Fianchi L, La Torre I, Zhong J, Laille E, Lopes de Menezes D, Skikne B, Beach CL, Giagounidis A. Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes. J Clin Oncol. 2021 May 1;39(13):1426-1436. Epub 2021 Mar 25. link to original article contains dosing details in manuscript link to PMC article PubMed NCT01566695
Erythropoietin monotherapy
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Fenaux et al. 2018 (EPOANE3021) | 2011-2014 | Phase 3 (E-esc) | Placebo | Superior erythroid response through week 24 |
Growth factor therapy
References
- EPOANE3021: Fenaux P, Santini V, Spiriti MAA, Giagounidis A, Schlag R, Radinoff A, Gercheva-Kyuchukova L, Anagnostopoulos A, Oliva EN, Symeonidis A, Berger MH, Götze KS, Potamianou A, Haralampiev H, Wapenaar R, Milionis I, Platzbecker U. A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS. Leukemia. 2018 Dec;32(12):2648-2658. Epub 2018 Mar 30. link to original article link to PMC article PubMed NCT01381809
Erythropoetin & Lenalidomide
Regimen variant #1, dose-reduced lenalidomide
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
List et al. 2021 (ECOG E2905) | 2009-2016 | Phase 3 (E-esc) | Lenalidomide | Superior MER |
Note: patients in ECOG E2905 were reassessed after cycle 4 and discontinued treatment if they did not have a MER. This dose was intended for patients with a pre-treatment platelet count of 50 x 109 to 99 x 109 or an ANC of 500/uL to 999/uL.
Targeted therapy
- Lenalidomide (Revlimid) 5 mg PO once per day on days 1 to 21
Growth factor therapy
- Epoetin beta (Recormon) 60,000 units SC once per day on days 1, 8, 15, 22
28-day cycles
Regimen variant #2
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
List et al. 2021 (ECOG E2905) | 2009-2016 | Phase 3 (E-esc) | Lenalidomide | Superior MER |
Toma et al. 2015 (GFM-Len-Epo-08) | 2010-2012 | Phase 3 (E-esc) | Lenalidomide | Seems to have superior erythroid response per IWG 2006 criteria |
Note: patients in ECOG E2905 were reassessed after cycle 4 and discontinued treatment if they did not have a MER.
Targeted therapy
- Lenalidomide (Revlimid) 10 mg PO once per day on days 1 to 21
Growth factor therapy
- Epoetin beta (Recormon) 60,000 units SC once per day on days 1, 8, 15, 22
28-day cycles
Regimen variant #3
Study | Evidence |
---|---|
Komrokji et al. 2012 (CC-5013-PK-002) | Phase 2 |
Note: this regimen is for erythroid nonresponders or those with relapsed anemia after 16 weeks of lenalidomide monotherapy.
Targeted therapy
- Lenalidomide (Revlimid) 10 to 15 mg PO once per day
Growth factor therapy
- Epoetin alfa (Procrit) 40,000 units SC once per day on days 1, 8, 15, 22
28-day cycles
References
- CC-5013-PK-002: Komrokji RS, Lancet JE, Swern AS, Chen N, Paleveda J, Lush R, Saba HI, List AF. Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome. Blood. 2012 Oct 25;120(17):3419-24. Epub 2012 Aug 30. link to original article contains dosing details in abstract PubMed NCT00910858
- GFM-Len-Epo-08: Toma A, Kosmider O, Chevret S, Delaunay J, Stamatoullas A, Rose C, Beyne-Rauzy O, Banos A, Guerci-Bresler A, Wickenhauser S, Caillot D, Laribi K, De Renzis B, Bordessoule D, Gardin C, Slama B, Sanhes L, Gruson B, Cony-Makhoul P, Chouffi B, Salanoubat C, Benramdane R, Legros L, Wattel E, Tertian G, Bouabdallah K, Guilhot F, Taksin AL, Cheze S, Maloum K, Nimuboma S, Soussain C, Isnard F, Gyan E, Petit R, Lejeune J, Sardnal V, Renneville A, Preudhomme C, Fontenay M, Fenaux P, Dreyfus F. Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion. Leukemia. 2016 Apr;30(4):897-905. Epub 2015 Oct 26. link to original article contains dosing details in abstract PubMed NCT01718379
- ECOG E2905: List AF, Sun Z, Verma A, Bennett JM, Komrokji RS, McGraw K, Maciejewski J, Altman JK, Cheema PS, Claxton DF, Luger SM, Mattison RJ, Wassenaar TR, Artz AS, Schiffer CA, Litzow MR, Tallman MS. Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin. J Clin Oncol. 2021 Mar 20;39(9):1001-1009. Epub 2021 Jan 13. link to original article contains dosing details in supplement PubMed NCT00843882
Lenalidomide monotherapy
Regimen variant #1, 5 mg continuous
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Fenaux et al. 2011 (CC-5013-MDS-004) | 2005-2007 | Phase 3 (E-esc) | Placebo | Superior primary endpoint |
Santini et al. 2016 (MDS-005) | 2010-2013 | Phase 3 (E-esc) | Placebo | Superior RBC transfusion independence ≥ 8 weeks |
Note: in MDS-005, this was the dose used for patients with CrCl 40 to 60 mL/min/1.73m2.
Regimen variant #2, 10 mg/day continuous
FDA-recommended dose |
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
List et al. 2005 (CC-5013-MDS-001) | 2002-2003 | Phase 2, <20 pts | ||
List et al. 2006 (CC-5013-MDS-003) | 2003-2004 | Phase 2 (RT) | ||
Raza et al. 2008 (CC-5013-MDS-002) | 2003-NR | Phase 2 | ||
Santini et al. 2016 (MDS-005) | 2010-2013 | Phase 3 (E-esc) | Placebo | Superior RBC transfusion independence ≥ 8 weeks |
Regimen variant #3, 10 mg 21/28
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
List et al. 2005 (CC-5013-MDS-001) | 2002-2003 | Phase 2, <20 pts | ||
Fenaux et al. 2011 (CC-5013-MDS-004) | 2005-2007 | Phase 3 (E-esc) | Placebo | Superior primary endpoint |
Toma et al. 2015 (GFM-Len-Epo-08) | 2010-2012 | Phase 3 (C) | Erythropoetin & Lenalidomide | Seems to have inferior erythroid response per IWG 2006 criteria |
References
- CC-5013-MDS-001: List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis JB. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005 Feb 10;352(6):549-57. link to original article PubMed
- CC-5013-MDS-003: List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, Powell B, Greenberg P, Thomas D, Stone R, Reeder C, Wride K, Patin J, Schmidt M, Zeldis J, Knight R; Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006 Oct 5;355(14):1456-65. link to original article contains dosing details in abstract PubMed NCT00065156
- CC-5013-MDS-002: Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ, Dreisbach L, Schiffer CA, Stone RM, Greenberg PL, Curtin PT, Klimek VM, Shammo JM, Thomas D, Knight RD, Schmidt M, Wride K, Zeldis JB, List AF. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008 Jan 1;111(1):86-93. Epub 2007 Sep 24. link to original article contains dosing details in abstract PubMed NCT00064974
- CC-5013-MDS-004: Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M, Muus P, Te Boekhorst P, Sanz G, Del Cañizo C, Guerci-Bresler A, Nilsson L, Platzbecker U, Lübbert M, Quesnel B, Cazzola M, Ganser A, Bowen D, Schlegelberger B, Aul C, Knight R, Francis J, Fu T, Hellström-Lindberg E; MDS-004 Lenalidomide del5q Study Group. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011 Oct 6;118(14):3765-76. Epub 2011 Jul 13. link to original article PubMed NCT00179621
- MDS-005: Santini V, Almeida A, Giagounidis A, Gröpper S, Jonasova A, Vey N, Mufti GJ, Buckstein R, Mittelman M, Platzbecker U, Shpilberg O, Ram R, Del Cañizo C, Gattermann N, Ozawa K, Risueño A, MacBeth KJ, Zhong J, Séguy F, Hoenekopp A, Beach CL, Fenaux P. Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents. J Clin Oncol. 2016 Sep 1;34(25):2988-96. Epub 2016 Jun 27. link to original article PubMed NCT01029262
- GFM-Len-Epo-08: Toma A, Kosmider O, Chevret S, Delaunay J, Stamatoullas A, Rose C, Beyne-Rauzy O, Banos A, Guerci-Bresler A, Wickenhauser S, Caillot D, Laribi K, De Renzis B, Bordessoule D, Gardin C, Slama B, Sanhes L, Gruson B, Cony-Makhoul P, Chouffi B, Salanoubat C, Benramdane R, Legros L, Wattel E, Tertian G, Bouabdallah K, Guilhot F, Taksin AL, Cheze S, Maloum K, Nimuboma S, Soussain C, Isnard F, Gyan E, Petit R, Lejeune J, Sardnal V, Renneville A, Preudhomme C, Fontenay M, Fenaux P, Dreyfus F. Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion. Leukemia. 2016 Apr;30(4):897-905. Epub 2015 Oct 26. link to original article contains dosing details in abstract PubMed NCT01718379
- ECOG E2905: List AF, Sun Z, Verma A, Bennett JM, Komrokji RS, McGraw K, Maciejewski J, Altman JK, Cheema PS, Claxton DF, Luger SM, Mattison RJ, Wassenaar TR, Artz AS, Schiffer CA, Litzow MR, Tallman MS. Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin. J Clin Oncol. 2021 Mar 20;39(9):1001-1009. Epub 2021 Jan 13. link to original article PubMed NCT00843882
Luspatercept monotherapy
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Fenaux et al. 2020 (MEDALIST) | 2016-2017 | Phase 3 (E-RT-esc) | Placebo | Superior transfusion independence |
Growth factor therapy
- Luspatercept (Reblozyl) 1 mg/kg SC once on day 1
- Dose can be increased based upon response (see paper for details)
21-day cycle for 8 cycles
References
- MEDALIST: Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, Díez-Campelo M, Finelli C, Cazzola M, Ilhan O, Sekeres MA, Falantes JF, Arrizabalaga B, Salvi F, Giai V, Vyas P, Bowen D, Selleslag D, DeZern AE, Jurcic JG, Germing U, Götze KS, Quesnel B, Beyne-Rauzy O, Cluzeau T, Voso MT, Mazure D, Vellenga E, Greenberg PL, Hellström-Lindberg E, Zeidan AM, Adès L, Verma A, Savona MR, Laadem A, Benzohra A, Zhang J, Rampersad A, Dunshee DR, Linde PG, Sherman ML, Komrokji RS, List AF. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. N Engl J Med. 2020 Jan 9;382(2):140-151. link to original article contains dosing details in manuscript PubMed NCT02631070
Placebo
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Fenaux et al. 2011 (CC-5013-MDS-004) | 2005-2007 | Phase 3 (C) | Lenalidomide | Inferior primary endpoint |
Santini et al. 2016 (MDS-005) | 2010-2013 | Phase 3 (C) | Lenalidomide | Inferior RBC transfusion independence ≥ 8 weeks |
No active antineoplastic treatment.
References
- CC-5013-MDS-004: Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M, Muus P, Te Boekhorst P, Sanz G, Del Cañizo C, Guerci-Bresler A, Nilsson L, Platzbecker U, Lübbert M, Quesnel B, Cazzola M, Ganser A, Bowen D, Schlegelberger B, Aul C, Knight R, Francis J, Fu T, Hellström-Lindberg E; MDS-004 Lenalidomide del5q Study Group. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011 Oct 6;118(14):3765-76. Epub 2011 Jul 13. link to original article PubMed NCT00179621
- MDS-005: Santini V, Almeida A, Giagounidis A, Gröpper S, Jonasova A, Vey N, Mufti GJ, Buckstein R, Mittelman M, Platzbecker U, Shpilberg O, Ram R, Del Cañizo C, Gattermann N, Ozawa K, Risueño A, MacBeth KJ, Zhong J, Séguy F, Hoenekopp A, Beach CL, Fenaux P. Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents. J Clin Oncol. 2016 Sep 1;34(25):2988-96. Epub 2016 Jun 27. link to original article PubMed NCT01029262
- EPOANE3021: Fenaux P, Santini V, Spiriti MAA, Giagounidis A, Schlag R, Radinoff A, Gercheva-Kyuchukova L, Anagnostopoulos A, Oliva EN, Symeonidis A, Berger MH, Götze KS, Potamianou A, Haralampiev H, Wapenaar R, Milionis I, Platzbecker U. A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS. Leukemia. 2018 Dec;32(12):2648-2658. Epub 2018 Mar 30. link to original article link to PMC article PubMed NCT01381809
- MEDALIST: Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, Díez-Campelo M, Finelli C, Cazzola M, Ilhan O, Sekeres MA, Falantes JF, Arrizabalaga B, Salvi F, Giai V, Vyas P, Bowen D, Selleslag D, DeZern AE, Jurcic JG, Germing U, Götze KS, Quesnel B, Beyne-Rauzy O, Cluzeau T, Voso MT, Mazure D, Vellenga E, Greenberg PL, Hellström-Lindberg E, Zeidan AM, Adès L, Verma A, Savona MR, Laadem A, Benzohra A, Zhang J, Rampersad A, Dunshee DR, Linde PG, Sherman ML, Komrokji RS, List AF. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. N Engl J Med. 2020 Jan 9;382(2):140-151. link to original article contains dosing details in manuscript PubMed NCT02631070
First-line therapy
Alemtuzumab monotherapy
Regimen
Study | Evidence |
---|---|
Sloand et al. 2010 (NHLBI 05-H-0206) | Phase 2 |
Eligibility criteria
- Intermediate-1 MDS (RAEB-I, RA, or RARS)
Targeted therapy
- Alemtuzumab (Campath) 1 mg IV once on day 1, then 10 mg IV once per day on days 2 to 11
Supportive therapy
- PCP prophylaxis: Pentamidine (Nebupent) (dose not specified) INH once per month for at least 6 months
- Valacyclovir (Valtrex) (dose/schedule not specified) until CD4 count greater than 200/uL
- Ciprofloxacin (Cipro) (dose/schedule not specified) if ANC less than 500/uL
- Erythropoietin and G-CSF were permitted for severe anemia or neutropenia
11-day course
References
- NHLBI 05-H-0206: Sloand EM, Olnes MJ, Shenoy A, Weinstein B, Boss C, Loeliger K, Wu CO, More K, Barrett AJ, Scheinberg P, Young NS. Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions. J Clin Oncol. 2010 Dec 10;28(35):5166-73. Epub 2010 Nov 1. link to original article contains dosing details in manuscript link to PMC article PubMed NCT00217594
ATG (Horse) monotherapy
ATG: AntiThymocyte Globulin
Regimen
Study | Evidence |
---|---|
Molldrem et al. 1997 | Phase 2 |
Note: Molldrem et al. 2002 is a larger cohort that includes the patients reported in Molldrem et al. 1997.
Immunosuppressive therapy
- Antithymocyte globulin, horse ATG (Atgam) 40 mg/kg IV over 4 to 8 hours once per day on days 1 to 4
Supportive therapy
- Prednisone (Sterapred) 1 mg/kg/day (minimum of 40 mg) PO on days 1 to 10, then tapered to off during days 11 to 17
17-day course
References
- Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol. 1997 Dec;99(3):699-705. link to original article PubMed
- Update: Molldrem JJ, Leifer E, Bahceci E, Saunthararajah Y, Rivera M, Dunbar C, Liu J, Nakamura R, Young NS, Barrett AJ. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med. 2002 Aug 6;137(3):156-63. link to original article contains dosing details in abstract PubMed
- Retrospective: Sloand EM, Wu CO, Greenberg P, Young N, Barrett J. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol. 2008 May 20;26(15):2505-11. Epub 2008 Apr 14. link to original article link to PMC article PubMed
ATG (Rabbit) monotherapy
ATG: AntiThymocyte Globulin
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Komrokji et al. 2014 (RDCRN 5406) | 2007-2009 | Phase 2 |
Immunosuppressive therapy
- Antithymocyte globulin, rabbit ATG (Thymoglobulin) 2.5 mg/kg IV over at least 6 hours once per day on days 1 to 4
Supportive therapy
- Prednisone (Sterapred) 1 mg/kg/day PO, started 2 days before first dose and continued at full dose during the 4 days, then tapered over the subsequent 14 days (tapering schedule not described)
- Antibiotics per local practices
18-day course
References
- RDCRN 5406: Komrokji RS, Mailloux AW, Chen DT, Sekeres MA, Paquette R, Fulp WJ, Sugimori C, Paleveda-Pena J, Maciejewski JP, List AF, Epling-Burnette PK. A phase 2 multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction. Haematologica. 2014 Jul;99(7):1176-83. Epub 2014 Jan 31. link to original article contains dosing details in manuscript link to PMC article PubMed NCT00466843
ATG (Horse) & Cyclosporine
ATG & Cyclosporine: AntiThymocyte Globulin & Cyclosporine
ATG & CsA: AntiThymocyte Globulin & Cyclosporine A
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Passweg et al. 2010 (SAKK 33/99) | 2000-2006 | Phase 3 (E-esc) | Best supportive care | Seems to have superior hematologic RR at 6 mo |
Immunosuppressive therapy
- Antithymocyte globulin, horse ATG (Lymphoglobuline) 15 mg/kg IV once per day on days 1 to 5
- Cyclosporine (formulation/route/dose/schedule not specified) on days 1 to 180
6-month course
References
- SAKK 33/99: Passweg JR, Giagounidis AA, Simcock M, Aul C, Dobbelstein C, Stadler M, Ossenkoppele G, Hofmann WK, Schilling K, Tichelli A, Ganser A. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99. J Clin Oncol. 2011 Jan 20;29(3):303-9. Epub 2010 Dec 13. link to original article contains partial protocol PubMed NCT00004208
Azacitidine monotherapy
Regimen variant #1, 60 mg/m2, 5 days/cycle
Study | Years of enrollment | Evidence |
---|---|---|
Grövdal et al. 2010 | 2004-2006 | Phase 2 |
Note: this regimen was intended to be used for high-risk MDS patients in remission after induction therapy
Regimen variant #2, 75 mg/m2, 3 days/cycle
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Jabbour et al. 2017 (MDA 2012-0507) | 2012-2016 | Randomized Phase 2 (E-switch-ic) | Decitabine | Seems to have inferior ORR |
Regimen variant #3, 75 mg/m2, 5 days/cycle
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Fili et al. 2013 (MDSAZA0706) | 2008-2010 | Phase 2 | ||
Thépot et al. 2016 (GFM-Aza-Epo-2008-01) | 2009-2010 | Randomized Phase 2 (C) | Azacitidine & Epoetin | Did not meet primary endpoint of RBC transfusion independence after 6 cycles |
Note: Intended to be used for low-risk MDS patients who are symptomatic or intolerant to erythropoietin (MDSAZA0706) or resistant to erythropoietin (GFM-Aza-Epo-2008-01).
Chemotherapy
- Azacitidine (Vidaza) 75 mg/m2 SC once per day on days 1 to 5
Supportive therapy
- G-CSF or GM-CSF was allowed if ANC less than 200/uL and/or systemic infection
- Erythropoiesis-stimulating agents were not allowed
- Antimicrobial and antifungal prophylaxis (agents not specified) given if ANC less than 500/uL
28-day cycle for 8 cycles (MDSAZA0706) or up to 18 cycles (GFM-Aza-Epo-2008-01)
Regimen variant #4, 75 mg/m2, 7 days/cycle (uninterrupted)
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Silverman et al. 2002 (CALGB 9221) | 1994-1996 | Phase 3 (E-RT-esc) | Best supportive care | Seems to have superior OS |
Fenaux et al. 2009 (AZA-001) | 2004-2006 | Phase 3 (E-RT-esc) | Best supportive care | Superior OS Median OS: 24.5 vs 15 mo (HR 0.58, 95% CI 0.43-0.77) |
Sekeres et al. 2017 (SWOG S1117) | 2012-2014 | Randomized Phase 2 (C) | 1. Azacitidine & Lenalidomide | Did not meet primary endpoint of ORR |
2. Azacitidine & Vorinostat | Did not meet primary endpoint of ORR | |||
Dickinson et al. 2018 (SUPPORT) | 2014-2015 | Phase 3 (C) | Azacitidine & Eltrombopag | Superior primary endpoint |
Awaiting publication (SELECT-MDS-1) | 2021-2023 | Phase 3 (C) | Azacitidine & Tamibarotene | TBD |
Biomarker eligibility criteria
- SELECT-MDS-1: RARA positive
Chemotherapy
- Azacitidine (Vidaza) 75 mg/m2 IV or SC once per day on days 1 to 7
28-day cycles Depending on the study, given for at least 4 cycles, continued for 3 cycles beyond complete remission, or continued indefinitely
Regimen variant #5, 75 mg/m2, 7 days/cycle (5-2-2)
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Sekeres et al. 2017 (SWOG S1117) | 2012-2014 | Randomized Phase 2 (C) | 1. Azacitidine & Lenalidomide | Did not meet primary endpoint of ORR |
2. Azacitidine & Vorinostat | Did not meet primary endpoint of ORR | |||
Adès et al. 2022 (PANTHERMDS) | 2017-2019 | Phase 3 (C) | Azacitidine & Pevonedistat | Did not meet primary endpoint of EFS |
Awaiting publication (VERONA) | 2020-2025 | Phase 3 (C) | Azacitidine & Venetoclax | TBD |
Awaiting publication (SELECT-MDS-1) | 2021-2023 | Phase 3 (C) | Azacitidine & Tamibarotene | TBD |
Biomarker eligibility criteria
- SELECT-MDS-1: RARA positive
Chemotherapy
- Azacitidine (Vidaza) 75 mg/m2 IV or SC once per day on days 1 to 5, 8 & 9
28-day cycles
References
- CALGB 9221: Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JF. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002 May 15;20(10):2429-40. link to original article contains dosing details in manuscript PubMed
- HRQoL analysis: Kornblith AB, Herndon JE 2nd, Silverman LR, Demakos EP, Odchimar-Reissig R, Holland JF, Powell BL, DeCastro C, Ellerton J, Larson RA, Schiffer CA, Holland JC. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol. 2002 May 15;20(10):2441-52. link to original article PubMed
- Pooled update: Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL, Larson RA; CALGB. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006 Aug 20;24(24):3895-903. link to original article contains dosing details in abstract PubMed
- AZA-001: Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR; International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009 Mar;10(3):223-32. Epub 2009 Feb 21. link to original article contains dosing details in abstract link to PMC article PubMed NCT00071799
- Grövdal M, Karimi M, Khan R, Aggerholm A, Antunovic P, Astermark J, Bernell P, Engström LM, Kjeldsen L, Linder O, Nilsson L, Olsson A, Holm MS, Tangen JM, Wallvik J, Oberg G, Hokland P, Jacobsen SE, Porwit A, Hellström-Lindberg E. Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy. Br J Haematol. 2010 Aug;150(3):293-302. Epub 2010 May 20. link to original article contains dosing details in manuscript PubMed
- MDSAZA0706: Filì C, Malagola M, Follo MY, Finelli C, Iacobucci I, Martinelli G, Cattina F, Clissa C, Candoni A, Fanin R, Gobbi M, Bocchia M, Defina M, Spedini P, Skert C, Manzoli L, Cocco L, Russo D. Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes. Clin Cancer Res. 2013 Jun 15;19(12):3297-308. link to original article contains dosing details in manuscript PubMed NCT00897130
- GFM-Aza-Epo-2008-01: Thépot S, Ben Abdelali R, Chevret S, Renneville A, Beyne-Rauzy O, Prébet T, Park S, Stamatoullas A, Guerci-Bresler A, Cheze S, Tertian G, Choufi B, Legros L, Bastié JN, Delaunay J, Chaury MP, Sanhes L, Wattel E, Dreyfus F, Vey N, Chermat F, Preudhomme C, Fenaux P, Gardin C; Groupe Francophone des Myélodysplasies. A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents. Haematologica. 2016 Aug;101(8):918-25. Epub 2016 May 26. link to original article contains dosing details in manuscript link to PMC article PubMed NCT01015352
- SWOG S1117: Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M, Roulston D, Bloomfield CD, Moseley A, Nazha A, Zhang Y, Velasco MR, Gaur R, Atallah E, Attar EC, Cook EK, Cull AH, Rauh MJ, Appelbaum FR, Erba HP. Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol. 2017 Aug 20;35(24):2745-2753. Epub 2017 May 9. link to original article contains dosing details in manuscript PubMed NCT01522976
- MDA 2012-0507: Jabbour E, Short NJ, Montalban-Bravo G, Huang X, Bueso-Ramos C, Qiao W, Yang H, Zhao C, Kadia T, Borthakur G, Pemmaraju N, Sasaki K, Estrov Z, Cortes J, Ravandi F, Alvarado Y, Komrokji R, Sekeres MA, Steensma DP, DeZern A, Roboz G, Kantarjian H, Garcia-Manero G. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood. 2017 Sep 28;130(13):1514-1522. Epub 2017 Aug 3. link to original article contains dosing details in manuscript PubMed NCT01720225
- SUPPORT: Dickinson M, Cherif H, Fenaux P, Mittelman M, Verma A, Portella MSO, Burgess P, Ramos PM, Choi J, Platzbecker U; SUPPORT study investigators. Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia. Blood. 2018 Dec 20;132(25):2629-2638. Epub 2018 Oct 10. link to original article contains dosing details in abstract PubMed NCT02158936
- PANTHERMDS: Adès L, Girshova L, Doronin VA, Díez-Campelo M, Valcárcel D, Kambhampati S, Viniou NA, Woszczyk D, De Paz Arias R, Symeonidis A, Anagnostopoulos A, Munhoz EC, Platzbecker U, Santini V, Fram RJ, Yuan Y, Friedlander S, Faller DV, Sekeres MA. Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML. Blood Adv. 2022 Sep 13;6(17):5132-5145. link to original article PubMed NCT03268954
- SELECT-MDS-1: contains dosing details on CT.gov NCT04797780
- VERONA: contains dosing details on CT.gov NCT04401748
Azacitidine & Lenalidomide
Regimen variant #1, 7 days of azacitidine
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Sekeres et al. 2017 (SWOG S1117) | 2012-2014 | Randomized Phase 2 (E-esc) | 1. Azacitidine | Did not meet primary endpoint of ORR |
2. Azacitidine & Vorinostat | Not reported |
Chemotherapy
- Azacitidine (Vidaza) 75 mg/m2 IV or SC once per day on days 1 to 7
Targeted therapy
- Lenalidomide (Revlimid) 10 mg PO once per day on days 1 to 21
28-day cycles
Regimen variant #2, 5-2-2 azacitidine
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Sekeres et al. 2017 (SWOG S1117) | 2012-2014 | Randomized Phase 2 (E-esc) | 1. Azacitidine | Did not meet primary endpoint of ORR |
2. Azacitidine & Vorinostat | Not reported |
Chemotherapy
- Azacitidine (Vidaza) 75 mg/m2 IV or SC once per day on days 1 to 5, 8 & 9
Targeted therapy
- Lenalidomide (Revlimid) 10 mg PO once per day on days 1 to 21
28-day cycles
Regimen variant #3, 5 days of azacitidine
Study | Evidence |
---|---|
Sekeres et al. 2012 (CASE17Z05) | Phase 2 |
Chemotherapy
- Azacitidine (Vidaza) 75 mg/m2 IV once per day on days 1 to 5
Targeted therapy
- Lenalidomide (Revlimid) 10 mg PO once per day on days 1 to 21
28-day cycle for up to 7 cycles
Subsequent treatment
- Option to continue single agent azacitidine per MD discretion
References
- CASE17Z05: Sekeres MA, Tiu RV, Komrokji R, Lancet J, Advani AS, Afable M, Englehaupt R, Juersivich J, Cuthbertson D, Paleveda J, Tabarroki A, Visconte V, Makishima H, Jerez A, Paquette R, List AF, Maciejewski JP. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood. 2012 Dec 13;120(25):4945-51. Epub 2012 Aug 22. link to original article contains dosing details in abstract link to PMC article PubMed NCT00352001
- SWOG S1117: Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M, Roulston D, Bloomfield CD, Moseley A, Nazha A, Zhang Y, Velasco MR, Gaur R, Atallah E, Attar EC, Cook EK, Cull AH, Rauh MJ, Appelbaum FR, Erba HP. Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol. 2017 Aug 20;35(24):2745-2753. Epub 2017 May 9. link to original article contains dosing details in manuscript PubMed NCT01522976
Azacitidine & Vorinostat
Regimen variant #1, 7 days of azacitidine
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Verma et al. 2013 (Study 6898) | NR in abstract | Phase 2 | ||
Sekeres et al. 2017 (SWOG S1117) | 2012-2014 | Randomized Phase 2 (E-esc) | 1. Azacitidine | Did not meet primary endpoint of ORR |
2. Azacitidine & Lenalidomide | Not reported |
Note: this was schedule two from Study 6898, except that vorinostat was once per day in the phase II trial.
Chemotherapy
- Azacitidine (Vidaza) 75 mg/m2 IV or SC once per day on days 1 to 7
Targeted therapy
- Vorinostat (Zolinza) 300 mg PO twice per day on days 3 to 9
28-day cycles
Regimen variant #2, 5-2-2 azacitidine
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Sekeres et al. 2017 (SWOG S1117) | 2012-2014 | Randomized Phase 2 (E-esc) | 1. Azacitidine | Did not meet primary endpoint of ORR |
2. Azacitidine & Lenalidomide | Not reported |
Chemotherapy
- Azacitidine (Vidaza) 75 mg/m2 IV or SC once per day on days 1 to 5, 8 & 9
Targeted therapy
- Vorinostat (Zolinza) 300 mg PO twice per day on days 3 to 9
28-day cycles
References
- Abstract: Amit Verma, Rosalie Odchimar-Reissig, Eric J. Feldman, Shyamala C. Navada, Erin P Demakos, Maria R. Baer, Vesna Najfeld, Joseph A Sparano, Richard Piekarz. A Phase II Trial Of Epigenetic Modulators Vorinostat In Combination With Azacitidine (azaC) In Patients With The Myelodysplastic Syndrome (MDS): Initial Results Of Study 6898 Of The New York Cancer Consortium. Blood Nov 2013,122(21)386 link to original abstract NCT00392353
- SWOG S1117: Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M, Roulston D, Bloomfield CD, Moseley A, Nazha A, Zhang Y, Velasco MR, Gaur R, Atallah E, Attar EC, Cook EK, Cull AH, Rauh MJ, Appelbaum FR, Erba HP. Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol. 2017 Aug 20;35(24):2745-2753. Epub 2017 May 9. link to original article contains dosing details in manuscript PubMed NCT01522976
Best supportive care
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Silverman et al. 2002 (CALGB 9221) | 1994-1996 | Phase 3 (C) | Azacitidine | Seems to have inferior OS |
Greenberg et al. 2009 (ECOG E1996) | 1997-2004 | Phase 3 (C) | Epoetin]] +/- G-CSF | Inferior erythroid ORR |
Passweg et al. 2010 (SAKK 33/99) | 2000-2006 | Phase 3 (C) | ATG & CSA | Seems to have inferior hematologic RR at 6 mo |
Kantarjian et al. 2006 (D-0007) | 2001-2004 | Phase 3 (C) | Decitabine | Inferior ORR |
Lübbert et al. 2011 (EORTC LSG/GMDSSG 06011) | 2002-2007 | Phase 3 (C) | Decitabine | Did not meet primary endpoint of OS |
Fenaux et al. 2009 (AZA-001) | 2004-2006 | Phase 3 (C) | Azacitidine | Inferior OS |
Note: although EORTC LSG/GMDSSG 06011 had a significantly different PFS, it did not meet the primary endpoint of OS. No active antineoplastic therapy; included here because it was a comparator arm in several studies.
References
- CALGB 9221: Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JF. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002 May 15;20(10):2429-40. link to original article contains dosing details in manuscript PubMed
- HRQoL analysis: Kornblith AB, Herndon JE 2nd, Silverman LR, Demakos EP, Odchimar-Reissig R, Holland JF, Powell BL, DeCastro C, Ellerton J, Larson RA, Schiffer CA, Holland JC. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol. 2002 May 15;20(10):2441-52. link to original article PubMed
- Pooled update: Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL, Larson RA; CALGB. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006 Aug 20;24(24):3895-903. link to original article contains dosing details in abstract PubMed
- D-0007: Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, de Castro C, Ravandi F, Helmer R 3rd, Shen L, Nimer SD, Leavitt R, Raza A, Saba H. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006 Apr 15;106(8):1794-803. link to original article contains dosing details in abstract PubMed NCT00043381
- AZA-001: Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR; International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009 Mar;10(3):223-32. Epub 2009 Feb 21. link to original article contains dosing details in abstract link to PMC article PubMed content property of HemOnc.org NCT00071799
- ECOG E1996: Greenberg PL, Sun Z, Miller KB, Bennett JM, Tallman MS, Dewald G, Paietta E, van der Jagt R, Houston J, Thomas ML, Cella D, Rowe JM. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood. 2009 Sep 17;114(12):2393-400. Epub 2009 Jun 29. link to original article PubMed NCT00003138
- SAKK 33/99: Passweg JR, Giagounidis AA, Simcock M, Aul C, Dobbelstein C, Stadler M, Ossenkoppele G, Hofmann WK, Schilling K, Tichelli A, Ganser A. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99. J Clin Oncol. 2011 Jan 20;29(3):303-9. Epub 2010 Dec 13. link to original article contains partial protocol PubMed NCT00004208
- EORTC LSG/GMDSSG 06011: Lübbert M, Suciu S, Baila L, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Beeldens F, Muus P, Pflüger KH, Coens C, Hagemeijer A, Eckart Schaefer H, Ganser A, Aul C, de Witte T, Wijermans PW; European Organisation for Research and Treatment of Cancer Leukemia Group; German MDS Study Group. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol. 2011 May 20;29(15):1987-96. Epub 2011 Apr 11. link to original article contains dosing details in manuscript PubMed NCT00043134
- Subgroup analysis: Becker H, Suciu S, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Muus P, Pflüger KH, Hagemeijer A, Schaefer HE, Fiaccadori V, Baron F, Ganser A, Aul C, de Witte T, Wijermans PW, Lübbert M. Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG). Ann Hematol. 2015 Dec;94(12):2003-13. Epub 2015 Sep 24. link to original article PubMed
- MDS-005: Santini V, Almeida A, Giagounidis A, Gröpper S, Jonasova A, Vey N, Mufti GJ, Buckstein R, Mittelman M, Platzbecker U, Shpilberg O, Ram R, Del Cañizo C, Gattermann N, Ozawa K, Risueño A, MacBeth KJ, Zhong J, Séguy F, Hoenekopp A, Beach CL, Fenaux P. Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents. J Clin Oncol. 2016 Sep 1;34(25):2988-96. Epub 2016 Jun 27. link to original article PubMed NCT01029262
Clofarabine monotherapy
Regimen variant #1
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Faderl et al. 2012 | NR | Randomized Phase 2 (E-de-esc) | Clofarabine; 30 mg/m2 dosing | Did not meet primary endpoint of ORR |
Note: This randomized trial tested two doses of clofarabine, 15 mg/m2 and 30 mg/m2. Lower dose was less toxic and clinical activity was comparable
Chemotherapy
- Clofarabine (Clolar) 15 mg/m2 IV over 60 minutes once per day on days 1 to 5
Supportive therapy
- "Supportive care measures such as antibiotic prophylaxis (eg, levofloxacin, valacyclovir, and itraconazole or voriconazole), hematopoietic growth factors, and transfusions were provided as necessitated for optimal medical care of the patients." In order to decrease risk of liver function abnormalities, no antifungals were given on the days where clofarabine was given.
4- to 8-week cycle for up to 12 cycles
Regimen variant #2
Study | Evidence |
---|---|
Faderl et al. 2010 (MDACC 2005-0536) | Non-randomized |
Note: The initial dose was too toxic; 20 mg/m2 was the final dose level
Chemotherapy
- Clofarabine (Clolar) 20 mg/m2 PO once per day on days 1 to 5
Supportive therapy
- "Supportive care included anti-infectious prophylaxis (eg, levaquin, valacyclovir, and itraconazole or voriconazole), hematopoietic growth factors, and transfusions as judged indicated by the treating physician." In order to decrease risk of liver function abnormalities, no antifungals were given on the days where clofarabine was given.
4- to 8-week cycle for up to 12 cycles
References
- MDACC 2005-0536: Faderl S, Garcia-Manero G, Estrov Z, Ravandi F, Borthakur G, Cortes JE, O'Brien S, Gandhi V, Plunkett W, Byrd A, Kwari M, Kantarjian HM. Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol. 2010 Jun 1;28(16):2755-60. Epub 2010 Apr 26. link to original article contains dosing details in manuscript link to PMC article PubMed NCT00299156
- Faderl S, Garcia-Manero G, Jabbour E, Ravandi F, Borthakur G, Estrov Z, Gandhi V, Byrd AL, Kwari M, Cortes J, Kantarjian HM. A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Cancer. 2012 Feb 1;118(3):722-8. Epub 2011 Jul 12. link to original article contains dosing details in manuscript link to PMC article PubMed
Cyclosporine monotherapy
Regimen
Study | Evidence |
---|---|
Jonásova et al. 1998 | Pilot, <20 pts |
Immunosuppressive therapy
- Cyclosporine 2.5 to 3 mg/kg PO twice per day, adjusted to maintain therapeutic cyclosporine level of 100 to 300 ng/mL
References
- Jonásova A, Neuwirtová R, Cermák J, Vozobulová V, Mociková K, Sisková M, Hochová I. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol. 1998 Feb;100(2):304-9. link to original article contains dosing details in abstract PubMed
- Retrospective: Sloand EM, Wu CO, Greenberg P, Young N, Barrett J. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol. 2008 May 20;26(15):2505-11. Epub 2008 Apr 14. link to original article link to PMC article PubMed
Decitabine monotherapy
Regimen variant #1, 10 mg/m2, 10 days per cycle (IV)
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Kantarjian et al. 2007 | NR | Randomized Phase 2, <20 pts in this arm (E-esc) | 1. Decitabine; IV x 5 days per cycle | Seems to have inferior CR rate |
2. Decitabine; SC x 5 days per cycle | Not reported |
Chemotherapy
- Decitabine (Dacogen) 10 mg/m2 IV over 60 minutes once per day on days 1 to 10
28-day cycles
Regimen variant #2, 15 mg/m2, 3 days per cycle (IV)
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Kantarjian et al. 2006 (D-0007) | 2001-2004 | Phase 3 (E-RT-esc) | Best supportive care | Superior ORR |
Lübbert et al. 2011 (EORTC LSG/GMDSSG 06011) | 2002-2007 | Phase 3 (E-esc) | Best supportive care | Did not meet primary endpoint of OS |
Note: although EORTC LSG/GMDSSG 06011 had a significantly different PFS, it did not meet the primary endpoint of OS.
Chemotherapy
- Decitabine (Dacogen) 15 mg/m2 IV over 3 to 4 hours every 8 hours on days 1 to 3
42-day cycle for up to 10 cycles
Regimen variant #3, 20 mg/m2, 3 days per cycle (IV)
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Jabbour et al. 2017 (MDA 2012-0507) | 2012-2016 | Randomized Phase 2 (E-switch-ic) | Azacitidine | Seems to have superior ORR |
Chemotherapy
- Decitabine (Dacogen) 20 mg/m2 IV over 60 minutes once per day on days 1 to 3
28-day cycles
Regimen variant #4, 20 mg/m2, 3 days per cycle (SC)
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Garcia-Manero et al. 2013 (DACO-026) | 2008-2009 | Randomized Phase 2 (E-switch-ic) | Decitabine; SC weekly | Did not meet primary endpoint of OIR |
Note: cycle length was allowed to vary by +/- 3 days.
Chemotherapy
- Decitabine (Dacogen) 20 mg/m2 SC once per day on days 1 to 3
28-day cycle for up to 13 cycles (1 year)
Regimen variant #5, 20 mg/m2, 5 days per cycle (IV)
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Kantarjian et al. 2007 | NR | Randomized Phase 2 (E-switch-ic) | 1. Decitabine; IV x 10 days per cycle | Seems to have superior CR rate |
2. Decitabine; SC x 5 days per cycle | Seems to have superior CR rate | |||
Issa et al. 2014 | NR | Randomized Phase 2 (C) | Decitabine & Valproic acid | Did not meet efficacy endpoint |
Chemotherapy
- Decitabine (Dacogen) 20 mg/m2 IV over 60 minutes once per day on days 1 to 5
4- to 6-week cycles
Regimen variant #6, 20 mg/m2, 5 days per cycle (SC)
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Kantarjian et al. 2007 | NR | Randomized Phase 2, <20 pts in this arm (E-switch-ic) | 1. Decitabine; IV x 5 days per cycle | Seems to have inferior CR rate |
2. Decitabine; IV x 10 days per cycle | Not reported |
Regimen variant #7, 20 mg/m2, weekly (SC)
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Garcia-Manero et al. 2013 (DACO-026) | 2008-2009 | Randomized Phase 2 (E-switch-ic) | Decitabine; SC x 3 days per cycle | Did not meet primary endpoint of OIR |
Note: cycle length was allowed to vary by +/- 3 days.
Chemotherapy
- Decitabine (Dacogen) 20 mg/m2 SC once per day on days 1, 8, 15
28-day cycle for up to 13 cycles (1 year)
References
- D-0007: Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, de Castro C, Ravandi F, Helmer R 3rd, Shen L, Nimer SD, Leavitt R, Raza A, Saba H. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006 Apr 15;106(8):1794-803. link to original article contains dosing details in abstract PubMed NCT00043381
- Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JP. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007 Jan 1;109(1):52-7. Epub 2006 Aug 1. link to original article contains dosing details in abstract PubMed
- EORTC LSG/GMDSSG 06011: Lübbert M, Suciu S, Baila L, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Beeldens F, Muus P, Pflüger KH, Coens C, Hagemeijer A, Eckart Schaefer H, Ganser A, Aul C, de Witte T, Wijermans PW; European Organisation for Research and Treatment of Cancer Leukemia Group; German MDS Study Group. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol. 2011 May 20;29(15):1987-96. Epub 2011 Apr 11. link to original article contains dosing details in manuscript PubMed NCT00043134
- Subgroup analysis: Becker H, Suciu S, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Muus P, Pflüger KH, Hagemeijer A, Schaefer HE, Fiaccadori V, Baron F, Ganser A, Aul C, de Witte T, Wijermans PW, Lübbert M. Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG). Ann Hematol. 2015 Dec;94(12):2003-13. Epub 2015 Sep 24. link to original article PubMed
- DACO-026: Garcia-Manero G, Jabbour E, Borthakur G, Faderl S, Estrov Z, Yang H, Maddipoti S, Godley LA, Gabrail N, Berdeja JG, Nadeem A, Kassalow L, Kantarjian H. Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes. J Clin Oncol. 2013 Jul 10;31(20):2548-53. Epub 2013 Jun 3. link to original article contains dosing details in manuscript link to PMC article PubMed NCT00619099
- Issa JP, Garcia-Manero G, Huang X, Cortes J, Ravandi F, Jabbour E, Borthakur G, Brandt M, Pierce S, Kantarjian HM. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer. 2015 Feb 15;121(4):556-61. Epub 2014 Oct 21. link to original article contains dosing details in manuscript link to PMC article PubMed
- MDA 2012-0507: Jabbour E, Short NJ, Montalban-Bravo G, Huang X, Bueso-Ramos C, Qiao W, Yang H, Zhao C, Kadia T, Borthakur G, Pemmaraju N, Sasaki K, Estrov Z, Cortes J, Ravandi F, Alvarado Y, Komrokji R, Sekeres MA, Steensma DP, DeZern A, Roboz G, Kantarjian H, Garcia-Manero G. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood. 2017 Sep 28;130(13):1514-1522. Epub 2017 Aug 3. link to original article contains dosing details in manuscript PubMed NCT01720225
Decitabine and cedazuridine monotherapy
Regimen
FDA-recommended dose |
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Garcia-Manero et al. 2020 (ASTX727-01-B) | 2014-NR | Randomized Phase 2 (E-RT-switch-ic) | Decitabine | Not reported |
Note: this was a randomized crossover trial examining PK/PD, and was not designed to compare efficacy.
Chemotherapy
- Decitabine and cedazuridine (Inqovi) 35/100 mg PO once per day on days 1 to 5
28-day cycles
References
- ASTX727-01-B: Garcia-Manero G, Griffiths EA, Steensma DP, Roboz GJ, Wells R, McCloskey J, Odenike O, DeZern AE, Yee K, Busque L, O'Connell C, Michaelis LC, Brandwein J, Kantarjian H, Oganesian A, Azab M, Savona MR. Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study. Blood. 2020 Aug 6;136(6):674-683. link to original article link to PMC article contains dosing details in manuscript PubMed NCT02103478
- ASCERTAIN: NCT03306264
Low-dose Cytarabine monotherapy (LoDAC)
LoDAC: Low Dose Ara-C (Cytarabine)
LDAC: Low-dose Ara-C (Cytarabine)
Regimen variant #1, SC
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Miller et al. 1992 | NR | Phase 3 (E-esc) | Best supportive care | Did not meet efficacy endpoints |
Zwierzina et al. 2005 (EORTC 06903) | NR | Phase 3 (C) | 1. LoDAC & GM-CSF 2. LoDAC & IL-3 |
Did not meet primary endpoints of ORR/PFS |
Note: the cycle length is not explicitly defined in EORTC 06903. This is an experimental arm that did not meet its primary endpoint; included here because it was eventually used to establish this regimen as a standard comparator.
Chemotherapy
- Cytarabine (Ara-C) 10 mg/m2 SC twice per day on days 1 to 14
21-day cycle for up to 6 cycles
Regimen variant #2, CI
Study | Evidence |
---|---|
Wisch et al. 1983 | Non-randomized, <20 pts |
Note: this regimen is for historic reference.
Chemotherapy
- Cytarabine (Ara-C) 20 mg/m2/day IV continuous infusion over 7 to 21 days, started on day 1
4- to 6-week cycle for up to 2 cycles
References
- Wisch JS, Griffin JD, Kufe DW. Response of preleukemic syndromes to continuous infusion of low-dose cytarabine. N Engl J Med. 1983 Dec 29;309(26):1599-602. link to original article contains dosing details in manuscript PubMed
- Miller KB, Kim K, Morrison FS, Winter JN, Bennett JM, Neiman RS, Head DR, Cassileth PA, O'Connell MJ; ECOG; SWOG. The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study. Ann Hematol. 1992 Oct;65(4):162-8. Erratum in: Ann Hematol 1993 Mar;66(3):164. Kyungmann K [corrected to Kim K]. link to original article contains dosing details in abstract PubMed
- EORTC 06903: Zwierzina H, Suciu S, Loeffler-Ragg J, Neuwirtova R, Fenaux P, Beksac M, Harousseau J, Nuessler V, Cermak J, Solbu G, Willemze R, de Witte T, Amadori S; EORTC Leukemia Cooperative Group. Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group. Leukemia. 2005 Nov;19(11):1929-33. link to original article contains dosing details in manuscript PubMed
Temozolomide monotherapy
Regimen
Study | Evidence |
---|---|
Brandwein et al. 2014 | Phase 2 |
Note: Patient selection was based on MGMT expression by Western blot. See article for details.
Chemotherapy
- Temozolomide (Temodar) 200 mg/m2/day PO on days 1 to 7
- Complete responders could receive: 200 mg/m2/day PO on days 1 to 5
28-day cycle for up to 12 cycles
References
- Brandwein JM, Kassis J, Leber B, Hogge D, Howson-Jan K, Minden MD, Galarneau A, Pouliot JF. Phase II study of targeted therapy with temozolomide in acute myeloid leukaemia and high-risk myelodysplastic syndrome patients pre-screened for low O(6) -methylguanine DNA methyltransferase expression. Br J Haematol. 2014 Dec;167(5):664-70. Epub 2014 Aug 27. link to original article contains dosing details in abstract PubMed
Consolidation after first-line therapy
Busulfan & Cyclophosphamide, then allo HSCT
BuCy: Busulfan & Cyclophosphamide
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Kröger et al. 2017 (RICMAC) | 2004-2012 | Phase 3 (C) | Bu/Flu RIC allo HSCT | Might have inferior OS |
Chemotherapy
- Busulfan (Myleran) 3.2 mg/kg IV once per day on days -7 to -4 (total dose: 12.8 mg/kg)
- Cyclophosphamide (Cytoxan) 60 mg/kg IV once per day on days -3 and -2 (total dose: 120 mg/kg)
Immunotherapy
- Allogeneic stem cells transfused on day 0
GVHD prophylaxis
- Cyclosporine
- Methotrexate (MTX) "according to the discretion of the attending physician"
Supportive therapy
- Filgrastim (Neupogen) 450 mcg SC once per day, starting on day +5 and continued until ANC greater than 3000/μL
One course
References
- RICMAC: Kröger N, Iacobelli S, Franke GN, Platzbecker U, Uddin R, Hübel K, Scheid C, Weber T, Robin M, Stelljes M, Afanasyev B, Heim D, Deliliers GL, Onida F, Dreger P, Pini M, Guidi S, Volin L, Günther A, Bethge W, Poiré X, Kobbe G, van Os M, Brand R, de Witte T. Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial). J Clin Oncol. 2017 Jul 1;35(19):2157-2164. Epub 2017 May 2. link to original article PubMed NCT01203228
Relapsed or refractory
Best supportive care
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Garcia-Manero et al. 2016 (ONTIME) | 2010-2013 | Phase 3 (C) | Rigosertib | Did not meet primary endpoint of OS |
No active antineoplastic therapy; considered the standard of care for MDS relapsed/refractory to hypomethylating agents.
References
- ONTIME: Garcia-Manero G, Fenaux P, Al-Kali A, Baer MR, Sekeres MA, Roboz GJ, Gaidano G, Scott BL, Greenberg P, Platzbecker U, Steensma DP, Kambhampati S, Kreuzer KA, Godley LA, Atallah E, Collins R Jr, Kantarjian H, Jabbour E, Wilhelm FE, Azarnia N, Silverman LR; ONTIME study investigators. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. Lancet Oncol. 2016 Apr;17(4):496-508. Epub 2016 Mar 8. link to original article PubMed NCT01241500
Erlotinib monotherapy
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Komrokji et al. 2014 (MCC-15961) | 2009-2011 | Phase 2 |
Thepot et al. 2014 (GFM-ERLOTINIB-08) | NR in abstract | Phase 1/2 |
Note: This is the MTD in GFM-ERLOTINIB-08.
Targeted therapy
- Erlotinib (Tarceva) 150 mg PO once per day
References
- MCC-15961: Komrokji RS, Padron E, Yu D, Fulp WJ, Rodriguez Y, Tinsley S, List AF, Lancet JE. Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes. Am J Hematol. 2014 Aug;89(8):809-12. Epub 2014 May 16. link to full article link to PMC article PubMed NCT00977548
- GFM-ERLOTINIB-08: Thepot S, Boehrer S, Seegers V, Prebet T, Beyne-Rauzy O, Wattel E, Delaunay J, Raffoux E, Hunault M, Jourdan E, Chermat F, Sebert M, Kroemer G, Fenaux P, Adès L; Groupe Francophone des Myelodysplasies. A phase I/II trial of erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure. Leuk Res. 2014 Dec;38(12):1430-4. Epub 2014 Oct 7. link to original article PubMed
Midostaurin monotherapy
Regimen variant #1
Study | Evidence | Comparator |
---|---|---|
Fischer et al. 2010 (CPKC412A2104) | Randomized Phase 2, <20 pts in this subgroup (E-de-esc) | Midostaurin; 100 mg twice per day |
Regimen variant #2
Study | Evidence | Comparator |
---|---|---|
Fischer et al. 2010 (CPKC412A2104) | Randomized Phase 2, <20 pts in this subgroup (E-esc) | Midostaurin; 50 mg twice per day |
References
- CPKC412A2104: Fischer T, Stone RM, Deangelo DJ, Galinsky I, Estey E, Lanza C, Fox E, Ehninger G, Feldman EJ, Schiller GJ, Klimek VM, Nimer SD, Gilliland DG, Dutreix C, Huntsman-Labed A, Virkus J, Giles FJ. Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol. 2010 Oct 1;28(28):4339-45. Epub 2010 Aug 23. link to original article link to PMC article contains dosing details in manuscript PubMed NCT00045942
Response criteria
WHO International Working Group criteria (2000, modified in 2006)
- Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, Löwenberg B, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Wijermans PW, Gore S, Greenberg PL; World Health Organization (WHO) international working group. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000 Dec 1;96(12):3671-4. link to original article PubMed
- Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006 Jul 15;108(2):419-25. Epub 2006 Apr 11. link to original article PubMed
Prognosis
- IPSS (Medscape)
- IPSS-R calculator, Revised International Prognostic Scoring System calculator (mds-foundation.org)
- Advanced IPSS-R calculator, Revised International Prognostic Scoring System calculator (mds-foundation.org)